Advanced

Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.

Linderoth, Johan LU ; Ehinger, Mats LU ; Åkerman, Måns LU ; Cavallin-Ståhl, Eva LU ; Enblad, Gunilla; Erlanson, Martin and Jerkeman, Mats LU (2007) In European Journal of Haematology 79(2). p.146-149
Abstract
Objective: In this study, our aim was to investigate how different immunohistochemical techniques may influence the result of BCL6 positivity and categorization in germinal center (GC) and non-GC derived diffuse large B-cell lymphoma (DLBCL), as it has been proposed that classification of DLBCL according to cell-of-origin by immunohistochemistry may be performed as a routine procedure in the diagnostic workup. However, a number of technical issues need to be solved before introducing this as a standard technique. Methods: Tumor specimens from 122 patients with de novo stage II-IV disease, adequately treated with anthracycline-containing chemotherapy regimens were collected. Immunohistochemical expression of BCL6, CD10, and MUM-1/IRF4 was... (More)
Objective: In this study, our aim was to investigate how different immunohistochemical techniques may influence the result of BCL6 positivity and categorization in germinal center (GC) and non-GC derived diffuse large B-cell lymphoma (DLBCL), as it has been proposed that classification of DLBCL according to cell-of-origin by immunohistochemistry may be performed as a routine procedure in the diagnostic workup. However, a number of technical issues need to be solved before introducing this as a standard technique. Methods: Tumor specimens from 122 patients with de novo stage II-IV disease, adequately treated with anthracycline-containing chemotherapy regimens were collected. Immunohistochemical expression of BCL6, CD10, and MUM-1/IRF4 was examined using a tissue microarray (TMA) technique. BCL6 and CD10 were also evaluated on whole tissue sections. Results: Due to profound tissue heterogeneity, BCL6 showed a wide range of positivity, with a high number of false negative results by TMA (25% positive), compared to 53% on whole tissue sections (WTS). CD10 was more homogeneously expressed, and TMA results corresponded better to WTS. Consequently, the results from categorization into GC and non-GC DLBCL differed considerably by use of the two methods, and resulted in very different outcome in terms of overall survival. Conclusion: Immunohistochemical GC-status determined on TMA is not reliable enough to be used for individual treatment decisions in DLBCL, mostly due to difficulties in interpreting BCL6 status. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bCL6, microarray, tissue, diffuse large B-cell lymphoma, immunohistochemistry
in
European Journal of Haematology
volume
79
issue
2
pages
146 - 149
publisher
Wiley-Blackwell
external identifiers
  • wos:000248450800008
  • scopus:34447344536
ISSN
1600-0609
DOI
10.1111/j.1600-0609.2007.00892.x
language
English
LU publication?
yes
id
378af8a5-1e97-4c52-a6db-0190b4290156 (old id 540695)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17635238&dopt=Abstract
date added to LUP
2007-12-14 15:23:57
date last changed
2017-05-21 03:38:06
@article{378af8a5-1e97-4c52-a6db-0190b4290156,
  abstract     = {Objective: In this study, our aim was to investigate how different immunohistochemical techniques may influence the result of BCL6 positivity and categorization in germinal center (GC) and non-GC derived diffuse large B-cell lymphoma (DLBCL), as it has been proposed that classification of DLBCL according to cell-of-origin by immunohistochemistry may be performed as a routine procedure in the diagnostic workup. However, a number of technical issues need to be solved before introducing this as a standard technique. Methods: Tumor specimens from 122 patients with de novo stage II-IV disease, adequately treated with anthracycline-containing chemotherapy regimens were collected. Immunohistochemical expression of BCL6, CD10, and MUM-1/IRF4 was examined using a tissue microarray (TMA) technique. BCL6 and CD10 were also evaluated on whole tissue sections. Results: Due to profound tissue heterogeneity, BCL6 showed a wide range of positivity, with a high number of false negative results by TMA (25% positive), compared to 53% on whole tissue sections (WTS). CD10 was more homogeneously expressed, and TMA results corresponded better to WTS. Consequently, the results from categorization into GC and non-GC DLBCL differed considerably by use of the two methods, and resulted in very different outcome in terms of overall survival. Conclusion: Immunohistochemical GC-status determined on TMA is not reliable enough to be used for individual treatment decisions in DLBCL, mostly due to difficulties in interpreting BCL6 status.},
  author       = {Linderoth, Johan and Ehinger, Mats and Åkerman, Måns and Cavallin-Ståhl, Eva and Enblad, Gunilla and Erlanson, Martin and Jerkeman, Mats},
  issn         = {1600-0609},
  keyword      = {bCL6,microarray,tissue,diffuse large B-cell lymphoma,immunohistochemistry},
  language     = {eng},
  number       = {2},
  pages        = {146--149},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.},
  url          = {http://dx.doi.org/10.1111/j.1600-0609.2007.00892.x},
  volume       = {79},
  year         = {2007},
}